Geode Capital Management LLC increased its position in shares of Teladoc, Inc. (NYSE:TDOC) by 77.8% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 254,130 shares of the health services provider’s stock after buying an additional 111,187 shares during the period. Geode Capital Management LLC owned 0.47% of Teladoc worth $6,353,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in TDOC. FMR LLC boosted its stake in shares of Teladoc by 163.5% in the first quarter. FMR LLC now owns 8,103,237 shares of the health services provider’s stock worth $202,581,000 after buying an additional 5,028,237 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Teladoc by 8,826.7% in the first quarter. JPMorgan Chase & Co. now owns 1,606,535 shares of the health services provider’s stock worth $40,163,000 after buying an additional 1,588,538 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Teladoc by 211.1% in the first quarter. Alliancebernstein L.P. now owns 2,286,200 shares of the health services provider’s stock worth $57,155,000 after buying an additional 1,551,315 shares in the last quarter. Eagle Asset Management Inc. acquired a new position in Teladoc during the first quarter valued at approximately $32,598,000. Finally, Wellington Management Group LLP raised its position in Teladoc by 38.9% in the first quarter. Wellington Management Group LLP now owns 4,228,082 shares of the health services provider’s stock valued at $105,701,000 after buying an additional 1,183,435 shares during the last quarter. Institutional investors and hedge funds own 94.51% of the company’s stock.
Teladoc, Inc. (NYSE TDOC) opened at 29.50 on Friday. Teladoc, Inc. has a 52 week low of $14.00 and a 52 week high of $36.90. The stock’s market cap is $1.67 billion. The company has a 50-day moving average of $33.13 and a 200-day moving average of $27.90.
Teladoc (NYSE:TDOC) last issued its quarterly earnings data on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The firm had revenue of $44.60 million during the quarter, compared to analyst estimates of $44.39 million. During the same period last year, the business earned ($0.38) EPS. The firm’s revenue was up 68.3% compared to the same quarter last year. On average, analysts predict that Teladoc, Inc. will post ($1.44) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Teladoc, Inc. (TDOC) Shares Bought by Geode Capital Management LLC” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.com-unik.info/2017/08/19/geode-capital-management-llc-has-6-35-million-stake-in-teladoc-inc-tdoc-updated.html.
Several research firms have recently commented on TDOC. BidaskClub lowered shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Tuesday. Cowen and Company reissued an “outperform” rating and issued a $39.00 price objective (up previously from $36.00) on shares of Teladoc in a research note on Thursday, August 3rd. Piper Jaffray Companies reissued a “buy” rating and issued a $42.00 price objective on shares of Teladoc in a research note on Friday, July 28th. Zacks Investment Research lowered shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Finally, TheStreet lowered shares of Teladoc from a “c-” rating to a “d” rating in a research note on Monday, July 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Teladoc presently has an average rating of “Buy” and an average price target of $35.55.
In other Teladoc news, CEO Jason N. Gorevic sold 14,400 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $29.57, for a total value of $425,808.00. Following the completion of the sale, the chief executive officer now owns 822,961 shares of the company’s stock, valued at $24,334,956.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jason N. Gorevic sold 5,600 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $29.57, for a total value of $165,592.00. Following the transaction, the chief executive officer now owns 823,861 shares of the company’s stock, valued at $24,361,569.77. The disclosure for this sale can be found here. Insiders sold 107,186 shares of company stock valued at $3,352,950 in the last ninety days. 5.94% of the stock is owned by corporate insiders.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
What are top analysts saying about Teladoc Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teladoc Inc. and related companies.